The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Toshio Shimizu(Kansai Medical University), Amita Patnaik(South Texas Accelerated Research Therapeutics), Michael J. Wick(Texas Oncology), Kyriakos P. Papadopoulos(Texas Oncology), Aracely Cavazos(Texas Oncology), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Leslie Smetzer(Texas Oncology), Drew Rasco(Texas Oncology), Shelly Gunn(Texas Oncology), Lon Smith(Texas Oncology), Theresa A. Mays(Texas Oncology), G. Mangold(Texas Oncology), Cathy Alvarez(Texas Oncology), Brianne Kaiser(Texas Oncology), Muralidhar Beeram(Urology San Antonio)
Cited by 432
Related Papers
E-CELL: software environment for whole-cell simulation.
|Bioinformatics|1999|765
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590